Advertisement

Topics

Biothera Company Profile

15:15 EST 20th January 2019 | BioPortfolio

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer session at ESMO 2014. In this study, which evaluated the addition of Imprime PGG to bevacizumab and carboplatin/paclitaxel versus bevacizumab and chemotherapy alone, objective response rate was 60.4% versus 43.5%, duration of response was 10.3 months versus 5.6 months and median overall survival was 16.1 months versus 11.6 months. Similarly encouraging data have been observed in both squamous and non-squamous subjects in a second randomized Phase 2 study in 1st line NSCLC in combination with cetuximab and in studies in high-risk chronic lymphocytic leukemia and metastatic colorectal cancer. Imprime PGG is being evaluated in a phase 3 study in late stage metastatic colorectal cancer and planning is underway for an approvable study in NSCLC. Emerging research further shows that Imprime PGG can re-orient the larger immune microenvironment, affecting both innate and adaptive immune effector cells, including T cells, dendritic cells, macrophages and myeloid-derived suppressor cells.


News Articles [8 Associated News Articles listed on BioPortfolio]

Biothera and AZ enter head and neck cancer trial collaboration

Biothera Pharmaceuticals Inc. and AstraZeneca PLC teamed up to evaluate the latter’s Imfinzi (durvalumab) in combination with Biothera’s Imprime PGG to treat primary untreated locally advanced hea...

Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca

Imprime PGG is an innate immune trigger that activates anti-cancer T cells.  Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and...

Biothera Pharmaceuticals enters into immuno-oncology clinical trial collaboration with AstraZeneca

Imprime PGG is an innate immune trigger that activates anti-cancer T cells.  Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and...

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime...

Checkmate Pharmaceuticals Appoints Barry Labinger President & CEO

Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, whe...

Biothera Pharmaceutical Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryBiothera Pharmaceutical Inc Biothera Pharmaceuticals, a subsidiary of Biothera Holding Corp is a medical technology company that develops immunotherapies for the treatment of cancer. The compan...

Biothera Pharmaceutical Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryBiothera Pharmaceutical Inc Biothera Pharmaceuticals, a subsidiary of Biothera Holding Corp is a medical technology company that develops immunotherapies for the treatment of cancer. The compan...

Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing

Expanded Leadership Team and Funding Supports Advancement of Clinical Development of Checkmate’s TLR9 Agonist, CMP-001 Checkmate Pharmaceuticals Inc., a clinical stage bioph...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Biothera, the Immune Health Company

Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight ca...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune ...

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrate...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and ...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most r...

More Information about "Biothera" on BioPortfolio

We have published hundreds of Biothera news stories on BioPortfolio along with dozens of Biothera Clinical Trials and PubMed Articles about Biothera for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biothera Companies in our database. You can also find out about relevant Biothera Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record